The drug modeling software market was valued at US$ 6,205.22 million in 2019 and is projected to reach US$ 11,299.85 million by 2027; it is expected to grow at a CAGR of 8.1% from 2020 to 2027.
The drug modeling software market was valued at US$ 6,205.22 million in 2019 and is projected to reach US$ 11,299.85 million by 2027; it is expected to grow at a CAGR of 8.1% from 2020 to 2027.
Drug modeling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing a key role in the development of novel drugs. Software based methods such as molecular modeling, structure-based drug design, structure-based virtual screening, ligand interaction, and molecular dynamics are considered to be powerful tool for the investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. Additionally, appropriate implementation of these techniques may help in reducing drug designing and development cost. Increasing cost of the drug development coupled with increasing drug failures is likely to drive the growth of the drug modeling software market during the forecast period. However, the market is likely to get negatively impacted by the less adoption of drug modeling software in emerging countries.
Request Exclusive Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPRE00013619/
Drug modeling software Market Competition Landscape and Key Developments:
Based on product type, the drug modeling software market is segmented into database, software, and others. The software segment held the largest share of the market in 2019. Successful drug discovery, development, and launch of a single new drug into the market, costs about one billion dollars, and it requires nearly 12 years for accomplishing. High cost, insufficient and lengthy-time duration, high level of risk, uncertainty in the results, and highly complex procedures are the main challenges in developing a new drug.
To overcome these problems, there is a strong need to employ new and cost-effective drug discovery and designing methods, such as software and computer-aided drug design and molecular docking. For instance, the platform provided by Schrödinger has devoted decades to refining computational algorithms to accurately compute the essential properties of molecules. The company uses NVIDIA GPUs to generate and evaluate the petabytes of data to accelerate drug discovery, as an improvement over the traditional process of slow and expensive lab work.
Based on application, the drug modeling software market is segmented into drug discovery and development, medical imaging, computational physiological medicine, predictive analysis of drug targets, disease modeling, simulation software, cellular simulation, and others. The drug discovery process is complex and includes an interdisciplinary effort to design practical and commercially feasible drugs. In pharmaceutical, medicinal, and other scientific research, a computer plays a significant role in the development of new compounds in the quest for better therapeutic agents.
Crown Bioscience Inc.; Chemical Computing Group Ulc; Nimbus Therapeutics; Schrödinger, Inc.; Dassault Systèmes; Genedata Ag; Biognos Ab; Compugen Ltd; Acellera ltd.; and Leadscope, Inc plc are among the prominent players operating in the drug modeling software market. The market players are focused on organic strategies to sustain their position in the market. For instance, in March 2020, Crown Bioscience has launched two new liver fibrosis rodent models, which allows rapid and cost-effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis, and/or fibrosis reversal.
Increasing Adoption of Modeling Tools in Drug Discovery
The discovery and development of new drugs with potential therapeutic applications is a complex, expensive, and time-consuming venture. Considering these challenges, various novel technologies have been developed to increase the efficiency of the drug discovery process. Computational methodologies have become a crucial part of several drug discovery programs. From hit identification to lead optimization, techniques such as ligand or structure-based virtual screening are widely being used by many pharmaceutical companies. With the help of modeling, existing data can be leveraged to gain insights on product safety and effectiveness. Owing to the efficiency of computational methods, the FDA and EMA have included modeling to support efficient drug development. Nowadays, in-Silico design (computer-aided) is being utilized to expedite and facilitate hit identification, optimize the absorption, distribution, metabolism, and toxicity profile to avoid safety issues. Commonly used in-silico approaches include ligand-based drug design, structure-based drug design, and quantitative structure-activity.
These methods are faster and provide valuable insights to experimental findings and mechanisms of action. Moreover, various pharmaceutical companies have started adopting these techniques for better outcomes. For instance, in April 2020, Boehringer Ingelheim has partnered with Insilico Medicine to leverage artificial intelligence (AI) technology to identify potential therapeutic targets. These methods are highly beneficial in case of virus outbark and emergency development of drugs. For instance, in Aug 2020, Certara announced the development of a new biosimulation platform for COVID-19 vaccines. The company has partnered with pharmaceutical companies to speed up the drug discovery and development. Its QSP platforms have vast potential to improve biopharmaceutical research and development and inform decision-making. By creating virtual patients and virtual trials, this new vaccine platform will facilitate dosing strategies for a range of patients infected by COVID-19. Moreover, many research organizations have also started adopting drug modeling technologies for expediting the research process. For instance, Southwest Research Institute (SwRI) is expanding the capacity to virtually screen drug compounds for possible treatment of COVID-19 and other infectious diseases. Recently, SwRI increased the capacity of its Rhodium software to scan 250,000 drug compounds per day. Thus, above mentioned factors are expected to drive the growth of the drug modeling software market during the forecast period.
Purchase a copy of the report @ https://www.theinsightpartners.com/buy/TIPRE00013619/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com